Get the Stockscreener App
7.67
2.91%
-0.23
After Hours:
7.67
Pulmatrix Inc stock is traded at $7.67, with a volume of 44,487.
It is down -2.91% in the last 24 hours and up +11.81% over the past month.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
See More
Previous Close:
$7.90
Open:
$7.9
24h Volume:
44,487
Relative Volume:
0.10
Market Cap:
$28.01M
Revenue:
$11.68M
Net Income/Loss:
$-8.85M
P/E Ratio:
-3.1826
EPS:
-2.41
Net Cash Flow:
$-14.61M
1W Performance:
+11.32%
1M Performance:
+11.81%
6M Performance:
+256.74%
1Y Performance:
+323.78%
1-Day Range:
$7.67
$8.14
1-Week Range:
$6.84
$8.14
52-Week Range:
$1.55
$8.4399
Pulmatrix Inc Stock (PULM) Company Profile
Name
Pulmatrix Inc
Sector
Industry
Phone
(888) 355-4440
Address
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
7.67 | 28.01M | 11.68M | -8.85M | -14.61M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-18 | Initiated | H.C. Wainwright | Buy |
Pulmatrix Inc Stock (PULM) Latest News
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - The Manila Times
SEC Form 425 filed by Pulmatrix Inc. - Quantisnow
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com - Defense World
Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com - Defense World
Pulmatrix, Inc. Holds 2024 Annual Meeting of Stockholders – Final Voting Results Released - Defense World
Pulmatrix secures director positions and ratifies accounting firm - Investing.com India
Pulmatrix secures director positions and ratifies accounting firm By Investing.com - Investing.com Australia
StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM) - Defense World
Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com - Defense World
Cullgen Entering Public Market with Pulmatrix Merger - San Diego Business Journal
Pulmatrix Announces Third Quarter 2024 Financial Results and Pro - GuruFocus.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
Pulmatrix and Cullgen announce proposed merger - MSN
Stock Market News: Samfine Creation Holdings drops by 21.56% while Pulmatrix dropped by almost 15% during mid day trading - Business Upturn
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - AccessWire
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc.PULM - Marketscreener.com
Pulmatrix (STU:2PU) Dividends per Share : €0.00 (TTM As of Jun. 2024) - GuruFocus.com
Pulmatrix Shares Hit 52-Week High After News of Merger Deal - MarketWatch
Zai Lab aims to raise $200M; Kronos Bio to seek ‘strategic’ options - Endpoints News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, ENTO, PIK, PFC on Behalf of Shareholders - AccessWire
U.S. Stock market top gainers: AgEagle Aerial Systems surges by 151.55% while Gaxos.ai Inc gains 47.58% in ealry trading - Business Upturn
U.S. Stock market: Molecular Templates surges by 155.81% while Sow Good declines by 53.39% during mid day trading - Business Upturn
Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders - The Bakersfield Californian
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
PULM stock touches 52-week high at $2.8 amid market optimism - Investing.com India
PULM stock touches 52-week high at $2.8 amid market optimism By Investing.com - Investing.com South Africa
Pulmatrix and Cullgen to Merge - citybiz
U.S. Stock market gains: BTC Digital Ltd. gains 79.72%, Kaixin Holdings surges 57.91% during mid day trading - Business Upturn
Pulmatrix Shares Surge on Merger with Cullgen - MarketWatch
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders - Business Wire
Pulmatrix To Merge With Cullgen - Contract Pharma
Cullgen and Pulmatrix set for merger, eye clinical trials By Investing.com - Investing.com South Africa
Pulmatrix and Cullgen Announce Strategic Merger Agreement - TipRanks
Cullgen and Pulmatrix set for merger, eye clinical trials - Investing.com
Cullgen to Absorb Pulmatrix, Join Nasdaq - MarketWatch
Pulmatrix announces merger agreement with Cullgen - TipRanks
Pulmatrix and Cullgen Announce Proposed Merger - PR Newswire
Pulmatrix Third Quarter 2024 Earnings: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023) - Yahoo Finance
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Pulmatrix Inc. (PULM) Quarterly 10-Q Report - Quartzy
Pulmatrix Q3 Revenue Falls 78%, But Cash Runway Extended to 2026 Despite Challenges - StockTitan
Head-To-Head Contrast: Sage Therapeutics (NASDAQ:SAGE) and Pulmatrix (NASDAQ:PULM) - Defense World
Pulmatrix presents data on inhaled drug delivery platform - Reuters
Pulmatrix sets date for 2024 annual stockholders meeting By Investing.com - Investing.com South Africa
Pulmatrix sets date for 2024 annual stockholders meeting - Investing.com India
Pulmatrix Inc Stock (PULM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):